FDA’s Next Step to Real-World Evidence: Prove That Real-World Studies Can Match Known RCT Results
This article was originally published in RPM Report
Industry is eager to develop approval pathways that rely on “real world” evidence from insurance claims and electronic health records. FDA, however, thinks the next step needs to be develop and validate the methodology.
You may also be interested in...
Effort to replicate clinical trial results with real-world data could eventually allow for increased use in drug development.
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.
Positive tandem ICER reviews for bluebird bio’s and Vertex/CRISPR’s gene therapies show the impact that concerns about addressing racial inequities could create a favorable context for products as they enter pricing and coverage discussions.